Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Merck
AstraZeneca
Cantor Fitzgerald
Cerilliant
UBS
Express Scripts
Federal Trade Commission
Baxter

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,907,135

« Back to Dashboard

Summary for Patent: 7,907,135
Title:Image display and image displaying method for gradation correction
Abstract: A projector 1 detects a luminance distribution in an effective video period of an inputted video luminance signal, and a coefficient calculating circuit 302 calculates a correction coefficient C.sub.i to correct a gradation (FIG. 6A). Then, surrounding brightness is detected, and the correction coefficient C.sub.i is adjusted based on the surrounding brightness to obtain an adjusted correction coefficient C.sub.i' (FIG. 6B). As shown in FIG. 6C, a luminance can be raised to Q according to a brightness signal even for a pixel of a lowest input luminance by adjusting the correction coefficient. Other correction coefficients in a range of 0 to 255 before adjustment are proportionally distributed to a range of 0 to 255-Q, and added with a correction coefficient Q. A luminance of each pixel which belongs to the effective video period of the video luminance signal is adjusted using the adjusted correction coefficient.
Inventor(s): Kuwabara; Akihiro (Nara, JP), Kimoto; Takayuki (Osaka, JP), Seki; Yoshio (Osaka, JP)
Assignee: Panasonic Corporation (Osaka, JP)
Application Number:11/721,965
Patent Claim Types:
see list of patent claims
Device; Use;

Drugs Protected by US Patent 7,907,135

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,907,135

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-095740Mar 29, 2005
PCT Information
PCT FiledFebruary 28, 2006PCT Application Number:PCT/JP2006/303802
PCT Publication Date:October 05, 2006PCT Publication Number: WO2006/103862

International Patents Family Members for US Patent 7,907,135

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 100493142 ➤ Subscribe
China 101151886 ➤ Subscribe
European Patent Office 1865709 ➤ Subscribe
Japan 4950031 ➤ Subscribe
Japan WO2006103862 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2006103862 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Citi
McKesson
Boehringer Ingelheim
Queensland Health
Farmers Insurance
Novartis
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot